Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of Sanofi SARS-CoV-2 adjuvanted recombinant protein vaccines (monovalent and bivalent) in adults
jRCT2031210159Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jul 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of monovalent [B.1.351] CoV2 preS dTM-AS03 and SARS-CoV-2 adjuvanted recombinant protein vaccine (D614 + B.1.351) in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Sanofi. Started Jul 2021; status: completed.
02
Drugs
monovalent [B.1.351] CoV2 preS dTM-AS03SARS-CoV-2 adjuvanted recombinant protein vaccine (D614 + B.1.351)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031210159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210159.